Abivax (ABVX) News Today $92.91 -2.70 (-2.82%) Closing price 04:00 PM EasternExtended Trading$92.77 -0.14 (-0.15%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Abivax (NASDAQ:ABVX) Research Coverage Started at BarclaysOctober 16 at 2:51 AM | americanbankingnews.comAbivax (NASDAQ:ABVX) Sets New 12-Month High - Still a Buy?October 15 at 6:31 AM | marketbeat.comAbivax: Betting Big On The Next Inflammatory Bowel Disease BlockbusterOctober 14 at 9:05 AM | seekingalpha.comAbivax (NASDAQ:ABVX) Upgraded by Barclays to Strong-Buy RatingOctober 14 at 8:01 AM | marketbeat.comBarclays Initiates Coverage of ABIVAX Société Anonyme - Depositary Receipt (ABVX) with Overweight RecommendationOctober 13 at 8:34 PM | msn.comAbivax initiated with an Overweight at BarclaysOctober 13 at 8:34 PM | msn.comAbivax (NASDAQ:ABVX) Shares Up 7.2% - Should You Buy?October 11, 2025 | marketbeat.comFY2027 EPS Estimates for Abivax Lifted by Leerink PartnrsOctober 11, 2025 | americanbankingnews.comAbivax (NASDAQ:ABVX) Hits New 12-Month High - Should You Buy?October 10, 2025 | marketbeat.comAbivax price target raised, named a ‘Best Idea’ at GuggenheimOctober 10, 2025 | msn.comA Look at Abivax (ENXTPA:ABVX) Valuation Following Phase 3 Success for Obefazimod in Ulcerative ColitisOctober 10, 2025 | finance.yahoo.comEquities Analysts Issue Forecasts for Abivax FY2027 EarningsOctober 10, 2025 | marketbeat.comAnalysts Set Abivax SA Sponsored ADR (NASDAQ:ABVX) PT at $102.14October 9, 2025 | americanbankingnews.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Abivax (NASDAQ:ABVX)October 8, 2025 | marketbeat.comBTIG Maintains ABIVAX Société Anonyme - Depositary Receipt (ABVX) Buy RecommendationOctober 8, 2025 | msn.comSpotlight on Abivax: Analyzing the Surge in Options ActivityOctober 6, 2025 | benzinga.comAbivax Shares Surge After Strong Phase 3 Results in Ulcerative Colitis StudyOctober 6, 2025 | msn.comAbivax (NASDAQ:ABVX) Sees Large Volume Increase - Still a Buy?October 6, 2025 | marketbeat.comAbivax’s Obefazimod: Promising Clinical Results and Market Potential Drive Buy RatingOctober 6, 2025 | tipranks.comABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call TranscriptOctober 6, 2025 | seekingalpha.comTop 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched DiseaseOctober 6, 2025 | investors.comAbivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced TherapiesOctober 6, 2025 | finance.yahoo.comAbivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 6, 2025 | marketbeat.comAbivax announces ABTECT 1, ABTECT 2 trials met primary endpointOctober 5, 2025 | msn.comAbivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety DataOctober 5, 2025 | globenewswire.comFY2025 EPS Estimates for Abivax Raised by Lifesci CapitalOctober 2, 2025 | marketbeat.comCitizens JMP Raises PT on ABIVAX Société Anonyme (ABVX) StockOctober 1, 2025 | msn.comABIVAX Société Anonyme (ABVX) to Present Phase 3 UC Data at UEG Congress, Investor Call ScheduledSeptember 30, 2025 | msn.comAbivax (NASDAQ:ABVX) Sees Strong Trading Volume - What's Next?September 30, 2025 | marketbeat.comPromising Phase 2b Results and Competitive Positioning Support Buy Rating for Abivax’s ObefazimodSeptember 29, 2025 | tipranks.comAbivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) MeetingSeptember 29, 2025 | globenewswire.comJMP Securities Maintains ABIVAX Société Anonyme - Depositary Receipt (ABVX) Market Outperform RecommendationSeptember 26, 2025 | msn.comAbivax price target raised to $114 from $95 at Citizens JMPSeptember 25, 2025 | msn.comAbivax (NASDAQ:ABVX) Stock Price Expected to Rise, JMP Securities Analyst SaysSeptember 25, 2025 | marketbeat.comAbivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) MeetingSeptember 23, 2025 | globenewswire.comOne new option listing on September 18thSeptember 18, 2025 | msn.comAbivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Increase in Short InterestSeptember 17, 2025 | marketbeat.comAbivax (NASDAQ:ABVX) Raised to "Hold" at Wall Street ZenSeptember 15, 2025 | marketbeat.comMorgan Stanley Issues Positive Forecast for Abivax (NASDAQ:ABVX) Stock PriceSeptember 14, 2025 | marketbeat.comAbivax (NASDAQ:ABVX) Shares Gap Down - What's Next?September 14, 2025 | marketbeat.comSA Asks: Which biotechs could be acquired by year's end?September 13, 2025 | msn.comAbivax (NASDAQ:ABVX) Shares Down 4.6% - Time to Sell?September 13, 2025 | marketbeat.comAbivax price target raised to $101 from $71 at Morgan StanleySeptember 12, 2025 | msn.comAbivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual ReviewSeptember 12, 2025 | globenewswire.comAbivax (NASDAQ:ABVX) Issues Earnings ResultsSeptember 12, 2025 | marketbeat.comAbivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of "Buy" by BrokeragesSeptember 12, 2025 | marketbeat.comBTIG Research Reaffirms "Buy" Rating for Abivax (NASDAQ:ABVX)September 11, 2025 | marketbeat.comOctagon Capital Advisors LP Takes $7.69 Million Position in Abivax SA Sponsored ADR $ABVXSeptember 11, 2025 | marketbeat.comABIVAX (ENXTPA:ABVX) Valuation in Focus After Steep Revenue Decline and Wider Losses in Latest EarningsSeptember 11, 2025 | uk.finance.yahoo.comABIVAX Société Anonyme (ENXTPA:ABVX) Completes $650 Million Follow-On Equity OfferingSeptember 10, 2025 | finance.yahoo.com Get Abivax News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABVX Media Mentions By Week ABVX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABVX News Sentiment▼0.530.72▲Average Medical News Sentiment ABVX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABVX Articles This Week▼153▲ABVX Articles Average Week Get the Latest News and Ratings for ABVX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Abivax and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BNTX News Today TEVA News Today GMAB News Today SMMT News Today ASND News Today RDY News Today VTRS News Today ROIV News Today BBIO News Today MRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABVX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO’s Regret: ‘I Wish I Gave [Elon] More’…Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
